Tenderwize
Wróć do wyszukiwania

Non-exclusive drug discount agreement for Dexamethasone (ATC S01BA01) via Open-House model

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Feb 28, 2027 · 185 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Dexamethason (ATC-Code nach WHO: S01BA01)

30/100

Ocena szansy

High riskLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

30 / 100

Złożoność

20 / 100

Czynniki ryzyka

The buyer may end the open-house procedure early if exclusive discount agreements are signed, which typically occur 8–1...

No minimum volumes; actual demand depends on patient prescriptions and pharmacy choices, which is unpredictable.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Weak opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Supply of Dexamethasone pharmaceutical products under a non-exclusive discount agreement.
  • Participation in the Open-House model; no negotiations or exclusivity.
Pokaż pełne podsumowanie

Non-exclusive drug discount agreement (Rabattvereinbarung) under §130a Abs. 8 SGB V for the active ingredient Dexamethasone (ATC S01BA01) via an Open-House model. Published by AOK PLUS for pharmaceutical companies. No guaranteed volumes; contract ends 28 February 2027. All qualified companies can participate during the participation period.

Ryzyka

The buyer may end the open-house procedure early if exclusive discount agreements are signed, which typically occur 8–1...

No minimum volumes; actual demand depends on patient prescriptions and pharmacy choices, which is unpredictable.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG.
  • Must accept the confidentiality and silence obligations regarding the agreement content.

Eligibility

  • Must submit required declarations (exclusion grounds, Russia sanctions).

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria applicable; all qualified participants are accepted. The notice states that award criteria fields are placeholders due to technical reasons.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive drug discount agreement for Dexamethasone (ATC S01BA01) via Open-House model

One lot covering all Dexamethasone pharmaceutical products. Open-house model: no exclusivity, no negotiations, no minimum volumes. Agreement valid until 28 February 2027.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Feb 2026 - Feb 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria applicable; all qualified participants are accepted. The notice states that award criteria fields are placeholders due to technical reasons.

Termin

Deadline Feb 28, 2027

Szczegóły zamówienia

Data publikacji
22 Dec 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
857590-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3